Pharmaceutical

Roche to acquire Poseida Therapeutics for $1.5bn

Roche has signed an agreement for the acquisition of Poseida Therapeutics in a deal representing a total value of up to $1.5bn.

Nov 27, 2024 - 06:00
Roche to acquire Poseida Therapeutics for $1.5bn
Roche has signed an agreement for the acquisition of Poseida Therapeutics in a deal representing a total value of up to $1.5bn.
Read the original article

Tags:

Previous Article

Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech   

Next Article

Shorla Oncology’s IMKELDI approved by FDA for leukaemia cancers

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Malaysia approves additional indication for Astrazeneca’s Evusheld

Malaysia approves additional indication for Astrazeneca...

Apr 10, 2023

STAT+: AstraZeneca buys early-stage gene therapies from Pfizer in boon for struggling field

STAT+: AstraZeneca buys early-stage gene therapies from...

Jul 28, 2023

STAT+: Health tech startups warn that overregulating AI could hamper innovation

STAT+: Health tech startups warn that overregulating AI...

Nov 23, 2023